Please login to the form below

Not currently logged in

J&J earnings top expectations, but feels the squeeze in US

Blockbuster Xarelto declines 14% due to US competition


Johnson & Johnson has released fourth quarter results showing better than expected overall growth, but also signs of a squeeze on some of its biggest products.

This includes cardiovascular blockbuster Xarelto, which saw a 14.4% decline, despite the FDA approving a new 2.5mg dose for those with chronic coronary or peripheral arterial disease (CAD/PAD).

The new approval increases Xarelto’s treatable patient population by around 13 million the US, but it was only given the go-ahead in October, making it too soon to see any resulting upturn in sales.

J&J chalked up the sales decline to a competitive US market, thrown into turmoil  last year by Trump’s drug pricing agenda.

This resulted in many pharma giants, including Novartis and Pfizer, freezing their drug prices and prompting further discounting the most competitive markets.

On yesterday's analyst call, the company said it remains excited by the potential to increase Xarelto’s treatable patient population with the new indication, and that initial customer response has been positive.

Nevertheless, the company's annual revenues rose almost 7% to $81.6bn, driven up by three rising star performers in particular: psoriasis treatment Stelara, leukaemia drug Imbruvica and multiple myeloma Darzalex.

Prostate cancer drug Zytiga sales fall 12.7% in the US thanks to new generic competition, while pulmonary hypertension medicine Tracleer declined by around 25% for the same reason.

The company is hoping to retain a share of the prostate cancer market, however, via its new treatment Erleada. The drug gained US approval last year, and has just gained marketing clearance in the EU.

Anti-inflammatory medicine Remicade also saw a sales drop  21% due to price reductions, but its still holding on to a remarkable 93% of its market share, holding out against biosimilar competition including Sandoz’ Zessly.

Its medical device division saw sales decline by $6.7bn, declining by 2.2%, and underperforming on Wall Street analysts predictions of $6.68bn.

Although the company says it expects the division to improve as it delivers “innovation that will have an enduring impact on patients, caregivers and consumers”.

This includes the progression of digital surgery platforms, while capitalising on its portfolio and accelerating growth strategy.

This time last year, the company improved the divisions’ operational growth by 1.1% compared to its previous year.

“We know we still have more work to do, and we are committed to returning to above-market growth in 2020,” it said.

23rd January 2019

From: Sales



COVID-19 Updates and Daily News

Featured jobs


Add my company
Videum Health

Videum Health is a premium video platform that offers brands innovative engagement strategies to reach targeted healthcare audiences on a...

Latest intelligence

How innovating study sites can improve patient recruitment efficiency
There are so many ways that clinical trials have innovated over the last few years. There is now a larger focus on making trials more patient-centric, more virtualised, and more...
Avoiding A Series of Unfortunate Events: launch lessons from lockdown
Chris Ross takes a novel look at launch excellence through the lens of COVID-19 and explores how pharma’s launch leaders are rewriting the story...
6 reasons patients drop out of clinical trials and 6 ways to fix it
If you’ve successfully recruited patients for your clinical trial, but one by one, they begin to drop out, then this information could be for you....